FindTrial
Sign In

A Randomised trial of Adjuvant Chemotherapy (ECF) in Biliary Cancer

A Randomised trial of Adjuvant Chemotherapy (ECF) in Biliary Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18496239
Enrollment
Unknown
Registered
2002-08-19
Start date
2000-01-01
Completion date
Unknown
Last updated
2020-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer Cancer Biliary

Interventions

Two Arms: 1. ECF - 5-Fluorouracil (5FU) 200 mg/m2 continuous infusion daily Epirubicin 50 mg/m2 3 weekly IV bolus Cisplatin 60 mg/m2 3 weekly 2. No treatment

Sponsors

Royal Marsden Hospital (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histological confirmed carcinoma of biliary tract or gall bladder 2. Disease considered to have been completely resected 3. No metastases on staging

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026